Vitreous floaters are a common symptom, estimated in one survey to affect two out of every three individuals, with one in three reporting visual impairment. When vitreous floaters measurably degrade vision, the diagnosis of vision degrading myodesopsia (VDM) can be established based on objective, quantitative criteria. The psychological features of depression and perceived stress associated with VDM have been extensively documented. Studies have further determined that patients with VDM would be willing to exchange 1 year of each remaining decade of life just to be rid of their floaters. This article explains the pathophysiology of VDM and the emerging treatment approaches.

**The Aging Process**

Vitreous is a clear gel in youth but undergoes significant structural changes with aging and myopia. The gel state and transparency of normal vitreous result from an intricate interaction between collagen and hyaluronan, which are initially homogeneously distributed throughout the vitreous body (Figure 1). Vitreous opacification results from fibrous liquefaction, a progressive process that begins in youth and advances more rapidly in myopic eyes, leading to myopic vitreopathy (Figure 2, Video 1). Fibrous liquefaction features dissociation of hydrophilic hyaluronan molecules from collagen, resulting in the formation of liquid vitreous and crosslinking/aggregation of vitreous collagen into structures that interfere with light passing through the center of the eye, casting perceptible shadows. When fibrous liquefaction of the vitreous body occurs in tandem with dehiscence of vitreoretinal adhesion, the result is a posterior vitreous detachment (PVD), the most common cause of vitreous floaters and VDM.

Even in the absence of the pathologic effects of anomalous PVD, the separation of the posterior vitreous cortex from the inner limiting membrane (ILM) can significantly disturb vision, due to light scattering. This is caused by the high density of collagen fibrils in the outer vitreous and/or folding...

**AT A GLANCE**

- Studies show that patients with vision degrading myodesopsia (VDM) would be willing to exchange 1 year of each remaining decade of life just to be rid of their floaters.
- Vitrectomy is a safe and effective treatment for VDM and can normalize contrast sensitivity within 1 week of surgery.
- Researchers are investigating the use of nanoparticles to enhance laser ablation of vitreous opacities.
of the outer vitreous, which is forced into a smaller surface area after separation from the ILM (Figure 3, Video 2). Opacities in the central vitreous and the outer shell of the vitreous body result in floaters and, in advanced cases, VDM.

Visual Significance

Recent investigations have determined that floaters can have a measurable effect on vision. While visual acuity is unaffected, studies have detected profound degradation in contrast sensitivity; one study found contrast sensitivity declined by 91% compared with age-matched controls. Investigations have correlated this degradation in contrast sensitivity with PVD, vitreous density by ultrasonography, and quality of life as measured by the National Eye Institute Visual Function Questionnaire. With the advent of quantitative ultrasonography to objectively assess vitreous structure and by measuring contrast sensitivity to evaluate visual function, clinicians are now able to quantitatively determine VDM severity to help guide management.

Treatment Advances

Although Nd:YAG laser vitreolysis has been widely employed to treat vitreous opacities, no definitive studies prove its efficacy. Thus, the United Kingdom National Institute for Health and Care Excellence (NICE) concluded that evidence on the safety and efficacy of Nd:YAG laser vitreolysis in the treatment of vitreous floaters is inadequate in quality and quantity. NICE officially recommended that Nd:YAG laser vitreolysis should only be used in the context of research and be done by retina specialists.

In contrast, vitrectomy is a safe and effective treatment for VDM. In one study of 139 consecutive cases, contrast sensitivity normalized within 1 week of surgery and remained normal for years thereafter. Moreover, vitrectomy for VDM was found to be more cost-effective than cataract surgery, amblyopia therapy, and retinal detachment (RD) repair.

To mitigate complications such as cataract and RD, limited vitrectomy was developed to preserve 3 mm to 4 mm of retrorenal gel vitreous and avoid surgical PVD induction. In a series of 195 cases, the incidence of retinal tears and RD was markedly reduced to 1.5% compared with traditional vitrectomy with surgical PVD induction, which has
a reported incidence of 30% for retinal tears and 6.8% to 10.9% for RD.23,25-27 Furthermore, the historically high incidence of cataract surgery following vitrectomy for floaters was reduced to 18% (mean follow-up of 20 months) in one study and 16.9% (mean follow-up of 32 months) in a larger study of limited vitrectomy for VDM.23,28 In these studies, cataract surgery was required in patients with a mean age of 64 ± 7 years. Importantly, when cataract surgery was performed, there were no complications related to the previous limited vitrectomy, perhaps due to the preservation of intact anterior gel vitreous.

**Pharmaceutical Intervention**

Despite the demonstrated safety and efficacy of limited vitrectomy for VDM for vitreous floaters, advanced therapeutics may be able to address this issue in the future. Pharmacologic vitreolysis has been approved for treating vitrectomy for VDM for vitreous floaters, advanced therapies which have an affinity for vitreous collagen. Once bound to collagen, these nanoparticles can absorb laser energy at levels 1,000 times lower than that of intact anterior gel vitreous.

**Clinical Implications**

Our past inability to properly evaluate the structural changes within the vitreous body and their effect on visual function has hampered our willingness to consider vitreous floaters as a disease. While most patients consider floaters a nuisance, some patients may have VDM. We must treat such patients with the same respect and consideration we afford to patients with other vitreoretinal diseases. In addition, we must commit ourselves to the development of novel diagnostic tools and therapeutics to address VDM and improve the quality of life for millions of patients worldwide.

Acknowledgments: Research discussed in this article was supported by the VMR Research Foundation. Alfredo A. Sadun, MD, PhD, FARVO, graciously reviewed this article.


J. SEBAG, MD, FACS, FRCOphth, FARVO

- Senior Research Scientist, Doheny Eye Institute, Pasadena, California
- Professor of Clinical Ophthalmology, Department of Ophthalmology, Geffen School of Medicine, University of California Los Angeles, Los Angeles
- Founding Director, VMR Institute for Vitreous Macula Retina, Huntington Beach, California
- jsebag@vmrinstitute.com
- Financial disclosure: Past Consultant (Alcon, Bayer, Bausch + Lomb, Genentech/ Roche, ThromboGenics); Patents - Minority (Nanobubble Technology, Quantitative Ultrasonography)